ArticleJAMA network open2020

Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.

Jing Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.